Your browser doesn't support javascript.
loading
Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.
Barbin, Laetitia; Rousseau, Chloe; Jousset, Natacha; Casey, Romain; Debouverie, Marc; Vukusic, Sandra; De Sèze, Jerome; Brassat, David; Wiertlewski, Sandrine; Brochet, Bruno; Pelletier, Jean; Vermersch, Patrick; Edan, Gilles; Lebrun-Frenay, Christine; Clavelou, Pierre; Thouvenot, Eric; Camdessanché, Jean-Philippe; Tourbah, Ayman; Stankoff, Bruno; Al Khedr, Abdullatif; Cabre, Philippe; Papeix, Caroline; Berger, Eric; Heinzlef, Olivier; Debroucker, Thomas; Moreau, Thibault; Gout, Olivier; Bourre, Bertrand; Créange, Alain; Labauge, Pierre; Magy, Laurent; Defer, Gilles; Foucher, Yohann; Laplaud, David A.
Afiliação
  • Barbin L; Authors' affiliations are listed at the end of the article.
  • Rousseau C; Authors' affiliations are listed at the end of the article.
  • Jousset N; Authors' affiliations are listed at the end of the article.
  • Casey R; Authors' affiliations are listed at the end of the article.
  • Debouverie M; Authors' affiliations are listed at the end of the article.
  • Vukusic S; Authors' affiliations are listed at the end of the article.
  • De Sèze J; Authors' affiliations are listed at the end of the article.
  • Brassat D; Authors' affiliations are listed at the end of the article.
  • Wiertlewski S; Authors' affiliations are listed at the end of the article.
  • Brochet B; Authors' affiliations are listed at the end of the article.
  • Pelletier J; Authors' affiliations are listed at the end of the article.
  • Vermersch P; Authors' affiliations are listed at the end of the article.
  • Edan G; Authors' affiliations are listed at the end of the article.
  • Lebrun-Frenay C; Authors' affiliations are listed at the end of the article.
  • Clavelou P; Authors' affiliations are listed at the end of the article.
  • Thouvenot E; Authors' affiliations are listed at the end of the article.
  • Camdessanché JP; Authors' affiliations are listed at the end of the article.
  • Tourbah A; Authors' affiliations are listed at the end of the article.
  • Stankoff B; Authors' affiliations are listed at the end of the article.
  • Al Khedr A; Authors' affiliations are listed at the end of the article.
  • Cabre P; Authors' affiliations are listed at the end of the article.
  • Papeix C; Authors' affiliations are listed at the end of the article.
  • Berger E; Authors' affiliations are listed at the end of the article.
  • Heinzlef O; Authors' affiliations are listed at the end of the article.
  • Debroucker T; Authors' affiliations are listed at the end of the article.
  • Moreau T; Authors' affiliations are listed at the end of the article.
  • Gout O; Authors' affiliations are listed at the end of the article.
  • Bourre B; Authors' affiliations are listed at the end of the article.
  • Créange A; Authors' affiliations are listed at the end of the article.
  • Labauge P; Authors' affiliations are listed at the end of the article.
  • Magy L; Authors' affiliations are listed at the end of the article.
  • Defer G; Authors' affiliations are listed at the end of the article.
  • Foucher Y; Authors' affiliations are listed at the end of the article.
  • Laplaud DA; Authors' affiliations are listed at the end of the article. david.laplaud@univ-nantes.fr.
Neurology ; 86(8): 771-8, 2016 Feb 23.
Article em En | MEDLINE | ID: mdl-26826205
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cloridrato de Fingolimode / Natalizumab / Imunossupressores / Esclerose Múltipla País/Região como assunto: Europa Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cloridrato de Fingolimode / Natalizumab / Imunossupressores / Esclerose Múltipla País/Região como assunto: Europa Idioma: En Ano de publicação: 2016 Tipo de documento: Article